Australia markets close in 3 hours 6 minutes
  • ALL ORDS

    7,684.00
    +34.40 (+0.45%)
     
  • ASX 200

    7,409.30
    +30.00 (+0.41%)
     
  • AUD/USD

    0.7376
    +0.0004 (+0.05%)
     
  • OIL

    72.72
    +0.33 (+0.46%)
     
  • GOLD

    1,814.90
    +15.20 (+0.84%)
     
  • BTC-AUD

    53,944.84
    -35.23 (-0.07%)
     
  • CMC Crypto 200

    931.25
    +1.32 (+0.14%)
     
  • AUD/EUR

    0.6219
    -0.0001 (-0.01%)
     
  • AUD/NZD

    1.0591
    +0.0001 (+0.01%)
     
  • NZX 50

    12,662.60
    +67.28 (+0.53%)
     
  • NASDAQ

    15,018.10
    +61.13 (+0.41%)
     
  • FTSE

    7,016.63
    +20.55 (+0.29%)
     
  • Dow Jones

    34,930.93
    -127.59 (-0.36%)
     
  • DAX

    15,570.36
    +51.23 (+0.33%)
     
  • Hang Seng

    26,065.32
    +591.44 (+2.32%)
     
  • NIKKEI 225

    27,687.28
    +105.62 (+0.38%)
     

Optic Nerve Diseases Pipeline: New Therapies to come for Debilitating Eye Diseases

·7-min read

Optic Nerve Diseases pipeline landscape offers 30+ Key companies and 30+ key therapies with gene therapy as a new treatment approach.

Los Angeles, USA, June 14, 2021 (GLOBE NEWSWIRE) -- Optic Nerve Diseases Pipeline: New Therapies to come for Debilitating Eye Diseases

Optic Nerve Diseases pipeline landscape offers 30+ Key companies and 30+ key therapies with gene therapy as a new treatment approach.

DelveInsight’s “Optic Nerve Diseases Pipeline Insight” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Optic Nerve Diseases pipeline landscapes. It comprises Optic Nerve Diseases pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Optic Nerve Diseases therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Optic Nerve Diseases pipeline products.

Some of the key takeaways from the Optic Nerve Diseases Pipeline Report

  • Notable companies such as Nicox Ophthalmics, GrayBug, Bio-Thera Solutions, Reistone Biopharma, Clene Nanomedicine, Chong Kun Dang Pharmaceutical, Qlaris Bio, Mitochon Pharmaceuticals, PYC Therapeutics, and others are developing potential drug candidates to boost the Optic Nerve Diseases treatment scenario.

  • Nicox and Ocumension Therapeutics have entered into an exclusive license agreement to develop and commercialize NCX 470 in the Chinese, Korean, and South East Asian markets.

  • In March 2021, Nicox SA declared that its partner, Ocumension Therapeutics, has secured approval from China’s Center for Drug Evaluation of the National Medical Products Administration to conduct the Chinese part of the ongoing NCX 470 Denali Phase 3 clinical trial for the decreasing of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  • In February 2021, Accure Therapeutics in collaboration with Neurotrials initiated a Phase II trial for evaluation of ACT-01 as an intravenous formulation for the treatment of acute optic neuritis (AON). (NCT04762017)

Get an overview of pipeline landscape @ Optic Nerve Diseases Clinical Trials Analysis

Optic Nerve Diseases are conditions that produce injury or dysfunction of the second cranial or optic nerve that is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, optic disk, nerve, optic chiasm, optic tract, or lateral geniculate nuclei.

Optic Nerve Diseases Emerging Drugs

  • NCX 470: Nicox Ophthalmics

NCX 470 is a new chemical entity formulated as an ophthalmic solution of this novel, second-generation nitric oxide (NO)-donating prostaglandin analog in development to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. NCX 470 is designed to release both bimatoprost and NO following instillation into the eye. It is currently in the Phase III stage of development and is being developed by Nicox Ophthalmics.

Research and Development
Phase III
NCT04630808: Nicox Ophthalmics, in November 2020, initiated “A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)”. This clinical study aims to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjects with ocular hypertension or open-angle glaucoma. The trial is expected to get finished by January 2023, with anticipated 670 enrolled participants.

Results

  • NCX 470 met the primary endpoint of non-inferiority and also showed superiority to latanoprost, the U.S. market leader in prostaglandin analog prescriptions, in several pre-specified analyses

  • Intraocular pressure (IOP) lowering effect from baseline of NCX 470 was 7.6 to 9.8 mmHg

  • All doses of NCX 470 were well tolerated with no drug-related serious adverse events.

  • CNM-Au8: Clene Nanomedicine

CNM-Au8 is a concentrated, aqueous suspension of clean surfaced faceted nanocrystalline gold (Au) in a drinkable bicarbonate solution. The drug enhances critical intracellular bioenergetic reactions necessary for repairing and reversing neuronal damage. CNM-Au8 has demonstrated safety in Phase 1 studies and has been shown to have remyelination and neuroprotective effects in preclinical models. The drug is in Phase III clinical studies for Amyotrophic lateral sclerosis treatment; Phase II/III clinical studies for multiple sclerosis and in Phase II clinical studies for optic nerve disorders.

Research and Development
Phase II
NCT03536559: Clene Nanomedicine, in November 2018 initiated “A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis”. The trial is expected to get finished by September 2022, with anticipated 150 enrolled participants.

The primary endpoint of the study is to evaluate the efficacy and safety of CNM-Au8 as a remyelinating therapy in patients with stable RMS. The secondary endpoint is the change in functional composite responder analysis score from Baseline to Week 24.

For further information, refer to the detailed report @ Optic Nerve Diseases Pipeline Therapeutics

Scope of Optic Nerve Diseases Pipeline Drug Insight

  • Coverage: Global

  • Major Players: 30+ Key Players

  • Prominent Players: Nicox Ophthalmics, GrayBug, Bio-Thera Solutions, Reistone Biopharma, Clene Nanomedicine, Chong Kun Dang Pharmaceutical, Qlaris Bio, Mitochon Pharmaceuticals, PYC Therapeutics, and many others.

  • Key Drugs Profiles: 30+ Products

  • Phases:

· Optic Nerve Diseases Therapies Late-stage (Phase III)
· Optic Nerve Diseases Therapies Mid-stage (Phase II)
· Optic Nerve Diseases Therapies Early-stage (Phase I)
· Optic Nerve Diseases Pre-clinical stage and Discovery candidates
· Discontinued and Inactive candidates

  • Mechanism of Action:

· Nitric oxide donors
· Agammaglobulinaemia tyrosine kinase inhibitors
· Carbonic anhydrase inhibitors
· KATP channel modulators
· Energy metabolism stimulants
· RNA interference
· Beta-adrenergic receptor antagonists
· Undefined mechanism
· Brain-derived neurotrophic factor expression modulators

  • Molecule Types:

· Stem Cell Therapy
· Small molecule
· Gene therapy

  • Route of Administration:

· Oral
· Inhalation
· Intravenous
· Subcutaneous

  • Product Types:

· Monotherapy
· Combination
· Mono/Combination

Key Questions regarding Current Optic Nerve Diseases Treatment Landscape and Emerging Therapies Answered in the Pipeline Report

  • What are the current options for Optic Nerve Diseases treatment?

  • How many companies are developing therapies for the treatment of Optic Nerve Diseases?

  • How many are Optic Nerve Diseases emerging therapies in the early-stage, mid-stage, and late development stages to treat Optic Nerve Diseases?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Optic Nerve Diseases market?

  • Which are the dormant and discontinued products and the reasons for the same?

  • What is the unmet need for current therapies for the treatment of Optic Nerve Diseases?

  • What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Optic Nerve Diseases therapies?

  • What are the critical designations that have been granted for the emerging therapies for Optic Nerve Diseases?

  • How many patents are granted and pending for the emerging therapies to treat Optic Nerve Diseases?

Table of Contents

1

Optic Nerve Diseases Report Introduction

2

Optic Nerve Diseases Executive Summary

3

Optic Nerve Diseases Overview

4

Optic Nerve Diseases – DelveInsight’s Analytical Perspective In-depth Commercial Assessment

5

Optic Nerve Diseases Pipeline Therapeutics

6

Optic Nerve Diseases Late Stage Products (Phase III)

6.1

NCX 470: Nicox Ophthalmics

7

Optic Nerve Diseases Mid Stage Products (Phase II)

7.1

QLS-101: Qlaris Bio

8

Optic Nerve Diseases Early Stage Products (Phase I)

8.1

MP101: Mitochon Pharmaceuticals

9

Optic Nerve Diseases Preclinical Stage Products

9.1

VP-002: PYC Therapeutics

10

Optic Nerve Diseases Therapeutic Assessment

11

Optic Nerve Diseases Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Optic Nerve Diseases Key Companies

14

Optic Nerve Diseases Key Products

15

Optic Nerve Diseases Unmet Needs

16

Optic Nerve Diseases Market Drivers and Barriers

17

Optic Nerve Diseases Future Perspectives and Conclusion

18

Optic Nerve Diseases Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Optic Nerve Diseases Drugs Pipeline Report

Related Reports

DelveInsight's Optic Nerve Diseases - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

Diabetic Eye Disease Market Research Report delivers an in-depth understanding of the Diabetic Eye Disease Market Size, Share, Pipeline Therapies, Key Companies, and Epidemiology Forecast.

DelveInsight's Eye Infections - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight's Eye Neoplasms - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight's Thyroid Eye Disease (TED) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

CONTACT: Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting